Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials.
Fiche publication
Date publication
novembre 2015
Journal
The Lancet. Haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FEUGIER Pierre
Tous les auteurs :
Maraldo MV, Giusti F, Vogelius IR, Lundemann M, van der Kaaij MA, Ramadan S, Meulemans B, Henry-Amar M, Aleman BM, Raemaekers J, Meijnders P, Moser EC, Kluin-Nelemans HC, Feugier P, Casasnovas O, Fortpied C, Specht L,
Lien Pubmed
Résumé
Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma.
Référence
Lancet Haematol. 2015 Nov;2(11):e492-502